Home | Erectile Dysfunction | New ED Drug Progresses to Market, May Provide Less Side Effects

New ED Drug Progresses to Market, May Provide Less Side Effects

Reviewed By,

Written By,

Reviewed By,

Written By,

It may take a few more years, but men may eventually have another FDA-approved alternative when it comes to providing effective treatment for erectile dysfunction (ED).

Pharmaceutical manufacturer Rexahn says their medication Zoraxel does not cause severe, rare side effects associated with Viagra/Cialis/Levitra. Zoraxel also stimulates neurotransmitters in the brain, whereas PDE-5 inhibitors only target end-organ erectile function and work in peripheral blood vessels.

Rexahn announced earlier this week that it has completed enrollment in its Phase IIa clinical trial evaluating Zoraxel. A drug may be introduced to the FDA for approval after successful Phase 3 testing. Potential introduction to the U.S. market, then, could reasonably be expected in a few years, just about the time the patent for Viagra will expire (March, 2012).

Read the Rexahn press release from earlier this week regarding Zoraxel.

Special Offers on Treatments and Products